Conference Call with Sequent Scientific Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Sequent Scientific announced Q1FY26 results Revenues: Rs 4,414 million compared to Rs 3,902 million during Q1FY25, change 13.1%. EBITDA: Rs 602 million compared to Rs 483 million during Q1FY25, change 24.7%. EBITDA Margin: 13.6% for Q1FY26. PAT: Rs 176 million compared to Rs 91 million during Q1FY25, change 93.7%. Rajaram Narayanan, Managing Director, said: “This quarter reinforces the momentum that we have built over the last 18 months, as we continue to deliver higher growth and profitability across all parts of the business. This has come on the back of initiatives in the areas relating to superior product mix, new launches and improved operational efficiency. Our proposed merger with Viyash Life Sciences is proceeding on plan and we expect all regulatory requirements to be completed in the next few months. We have commenced working on the Sequent 3.0 roadmap to leverage the synergies resulting from the merger and accelerate profitable revenue growth.” Result PDF